Lisocabtagene Maraleucel Associated With Manageable Toxicities, Deep Responses in Relapsed/Refractory CLL or SLL
Researchers sought to determine whether liso-cel would have acceptable toxicity and effectiveness in patients with SLL or CLL.
Diagnosis & Disease Information
Vaccine-Induced Responses to Omicron, Delta Impaired in Non-Hodgkin Lymphoma Patients
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
Clinical Advantages: Targeting BTK in CLL
Chronic lymphocytic leukemia (CLL) is a chronic incurable mature B-cell neoplasm that often does not require immediate treatment; however, when patients experience symptoms, such as anemia, cytopenias, or bulky lymphadenopathy, therapy is required. During a presentation at the 2022 Oncology Nurse Advisor Summit, Laura J. Zitella, MS, RN, ACNP-BC, AOCN, an associate clinical professor at…
Durable Remission Seen in Two CLL Patients After CAR T Cell Therapy
CAR T cells detectable more than 10 years after infusion with sustained remission in both patients.
Less Intensive Monitoring of Venetoclax May be Safe in Low-Risk CLL
A retrospective review of data from patients with CLL demonstrated varied adherence to guidelines for ramp up initiation and laboratory monitoring.
MRD Assessment Can Guide Treatment Discontinuation in CLL/SLL
Stopping treatment after induction did not impact disease-free survival in patients with undetectable minimal residual disease.
Cause of Death Varies by Risk Group in Chronic Lymphocytic Leukemia
For patients with low- or intermediate-risk disease, the risk of dying from CLL progression was similar to the risk of dying from CLL-related complications or from causes unrelated to CLL.
MRD Status Not Associated With PFS in Chronic Lymphocytic Leukemia Patients on Ibrutinib
Undetectable MRD was not associated with significantly better PFS at any time point.
Acalabrutinib Seems Safe and Efficacious in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Venetoclax-Obinutuzumab Doesn’t Impair Quality of Life in Patients With Chronic Lymphocytic Leukemia
Quality of life outcomes were generally the same from baseline through follow-up.
- Loading...
Loading...
Loading... 
Loading...